- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07192471
- Original rettssak
En første-i-menneskelig studie av KK2223 hos deltakere med tilbakefall eller ildfast T-celle ikke-Hodgkin lymfom
En fase 1, multisenter, åpen etikett, ikke-randomisert, dose-opptrapping og utfyllingsstudie av KK2223 hos deltakere med tilbakefall eller ildfast T-celle non Hodgkin lymfom
The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a Phase 1, multicenter, open-label, non randomized study in participants with relapsed or refractory PTCL or CTCL. This study consists of Part 1 (dose-escalation) and Part 2 (backfill). The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of K2223 in r/r T-cell NHL (PTCL or CTCL)
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Kyowa Kirin, Inc.
- Telefonnummer: +1-609-919-1100
- E-post: KKD.Clinical.82@kyowakirin.com
Studiesteder
-
-
California
-
Duarte, California, Forente stater, 91010
- Har ikke rekruttert ennå
- City of Hope
-
Hovedetterforsker:
- Christina Poh
-
Ta kontakt med:
- Christina Poh
- Telefonnummer: 916-734-7131
- E-post: cpoh@coh.org
-
Orange, California, Forente stater, 92868
- Har ikke rekruttert ennå
- University of California, Irvine Medical Center - Hematology/Oncology
-
Ta kontakt med:
- Lauren Pinter Brown
- Telefonnummer: 7144568200
- E-post: lpinterb@uci.edu
-
Hovedetterforsker:
- Lauren Pinter Brown
-
Stanford, California, Forente stater, 94305
- Rekruttering
- Stanford University School of Medicine
-
Hovedetterforsker:
- Youn Kim
-
Ta kontakt med:
- Youn Kim
- Telefonnummer: 650-723-7893
- E-post: younkim@stanford.edu
-
-
Florida
-
Tampa, Florida, Forente stater, 33612
- Har ikke rekruttert ennå
- Moffit Cancer Center
-
Ta kontakt med:
- Yumeng Zhang
- Telefonnummer: 844-304-8636
- E-post: yumeng.zhang@moffitt.org
-
Hovedetterforsker:
- Yumeng Zhang
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Har ikke rekruttert ennå
- Emory University Medical Center
-
Hovedetterforsker:
- Pamela Allen
-
Ta kontakt med:
- Pamela Allen
- Telefonnummer: 404-778-2407
- E-post: pallen5@emory.edu
-
-
Iowa
-
Iowa City, Iowa, Forente stater, 52242
- Har ikke rekruttert ennå
- University of Iowa Health
-
Hovedetterforsker:
- Eric Mou
-
Ta kontakt med:
- Eric Mou
- Telefonnummer: 800-777-8442
- E-post: eric-mou@uiowa.edu
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215
- Har ikke rekruttert ennå
- Beth Israel Deaconess Medical Center - Research
-
Ta kontakt med:
- Salvia Jain
- Telefonnummer: 617-726-2000
- E-post: salvia.jain@mgh.harvard.edu
-
Hovedetterforsker:
- Salvia Jain
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63110
- Rekruttering
- Washington University School of Medicine - Oncology Hospital - Public
-
Hovedetterforsker:
- Neha Mehta Shah
-
Ta kontakt med:
- Neha Mehta Shah
- Telefonnummer: 314.273-8566
- E-post: mehta-n@wustl.edu
-
-
New Jersey
-
Hackensack, New Jersey, Forente stater, 07601-2105
- Har ikke rekruttert ennå
- Hackensack University Medical Center - John Theurer Cancer C - Lymphoma Division
-
Hovedetterforsker:
- Tatyana Feldman
-
Ta kontakt med:
- Tatyana Feldman
- Telefonnummer: 551-996-5900
- E-post: tatyana.feldman@hmhn.org
-
-
New York
-
New York, New York, Forente stater, 10021-6007
- Rekruttering
- Memorial Sloan Kettering Cancer Center
-
Hovedetterforsker:
- Jasmine Zain
-
Ta kontakt med:
- Jasmine Zain
- Telefonnummer: 212-639-3045
- E-post: zainj1@mskcc.org
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44106
- Har ikke rekruttert ennå
- University Hospitals Cleveland Medical Center
-
Ta kontakt med:
- Kevin Cooper
- Telefonnummer: 216-844-8200
- E-post: kevin.cooper@uhhospitals.org
-
Hovedetterforsker:
- Kevin Cooper
-
-
Oregon
-
Portland, Oregon, Forente stater, 97239
- Har ikke rekruttert ennå
- Oregon Health & Science University
-
Ta kontakt med:
- Craig Okada
- Telefonnummer: 503-494-8397
- E-post: okadac@ohsu.edu
-
Hovedetterforsker:
- Craig Okada
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Har ikke rekruttert ennå
- University of Pennsylvania - Abramson Cancer Center
-
Hovedetterforsker:
- Stefan Barta
-
Ta kontakt med:
- Stefan Barta
- Telefonnummer: 215-728-2674
- E-post: Stefan.Barta@pennmedicine.upenn.edu
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- The University of Texas - MD Anderson Cancer Center
-
Hovedetterforsker:
- Ranjit Nair
-
Ta kontakt med:
- Ranjit Nair
- Telefonnummer: 171-379-2860
- E-post: rnair@mdanderson.org
-
-
-
-
-
Bergamo, Italia, 24127
- Har ikke rekruttert ennå
- Azienda Ospedaliera Papa Giovanni XXIII - Ematologia
-
Hovedetterforsker:
- Giuseppe Gritti
-
Ta kontakt med:
- Giuseppe Gritti
- Telefonnummer: 39035269492
- E-post: giuseppe_gritti@yahoo.it
-
Bologna, Italia, 40138
- Har ikke rekruttert ennå
- Azienda Ospedaliero Universitaria di Bologna IRCCS (Policlinico di Sant'Orsola) - Ematologia
-
Ta kontakt med:
- Luigi Zinzani Pier
- Telefonnummer: 390516363680
- E-post: pierluigi.zinzani@unibo.it
-
Hovedetterforsker:
- Luigi Zinzani Pier
-
Torino, Italia, 10126
- Har ikke rekruttert ennå
- AOU Citta' della Salute e della Scienza di Torino Ospedale Molinette, Ematologia Universitaria
-
Ta kontakt med:
- Federica Cavallo
- Telefonnummer: 390116334264
- E-post: f.cavallo@unito.it
-
Hovedetterforsker:
- Federica Cavallo
-
-
Torino
-
Candiolo, Torino, Italia, 10060
- Har ikke rekruttert ennå
- Istituto di Candiolo, IRCCS - Oncologia Medica ed Ematologia
-
Hovedetterforsker:
- Umberto Vitolo
-
Ta kontakt med:
- Umberto Vitolo
- Telefonnummer: 390116335934
- E-post: umberto.vitolo@ircc.it
-
-
-
-
-
Madrid, Spania, 28027
- Har ikke rekruttert ennå
- Clinica Universidad de Navarra - Hematología y Hemoterapia
-
Ta kontakt med:
- Miguel Canales Albendea
- Telefonnummer: 34917277116
- E-post: macanales@unav.es
-
Hovedetterforsker:
- Migue Canales Albendea
-
-
Barcelona
-
Badalona, Barcelona, Spania, 8036
- Har ikke rekruttert ennå
- Hospital Clinic De Barcelona - Hematología
-
Hovedetterforsker:
- Pablo Mozas
-
Ta kontakt med:
- Pablo Mozas
- Telefonnummer: 34 93 227 22 71
- E-post: mozas@clinic.cat
-
L'Hospitalet de Llobregat, Barcelona, Spania, 8907
- Har ikke rekruttert ennå
- Institut Català d'Oncologia (ICO) - ICO L'Hospitalet - Hematologia
-
Hovedetterforsker:
- Eva Domingo Domenech
-
Ta kontakt med:
- Eva Domingo Domenech
- Telefonnummer: 34932607822
- E-post: edomingo@iconcologia.net
-
-
Navarre
-
Pamplona, Navarre, Spania, 31008
- Har ikke rekruttert ennå
- Clinica Universidad de Navarra - Hematología
-
Ta kontakt med:
- Miguel Canales Albendea
- Telefonnummer: 34917277116
- E-post: macanales@unav.es
-
Hovedetterforsker:
- Miguel Canales Albendea
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Adults (≥18 years) with confirmed T-cell lymphoma subtypes: PTCL (including nodal T-follicular helper cell lymphoma, ALCL, PTCL NOS) for Parts 1 and 2; CTCL (mycosis fungoides or Sézary syndrome, stages IIB-IV) for Parts 1 and 2, with specific disease involvement criteria in Part 2.
- PTCL participants must have relapsed/refractory/intolerant to ≥1 systemic therapy; CD30+ PTCL must have prior brentuximab vedotin treatment or intolerance, and/or ALK-positive ALCL participants should have previously received crizotinib if indicated (crizotinib administration is applicable to US sites only). CTCL participants must have relapsed/refractory/intolerant to ≥2 systemic therapies.
- Availability of tumor tissue (current or archival) is required.
- Measurable disease required: nodal/extranodal lesions for PTCL and assessable skin disease for CTCL.
- ECOG performance status 0-1; adequate neutrophils (≥1000/µL), platelets (≥75,000/µL), renal function (creatinine clearance ≥60 mL/min), liver function within defined limits, and total bilirubin ≤1.5× ULN (up to 3× ULN with Gilbert's syndrome).
- Body weight 40 kg to ≤ 200 kg
- Life expectancy ≥3 months.
- Negative pregnancy test for females of childbearing potential; contraception required for females and males with partners of childbearing potential during and after treatment.
- Restrictions on gamete donation and freezing during and after treatment.
- Ability to provide informed consent and comply with study procedures. -
Exclusion Criteria:
- Recent autologous or allogeneic transplant within 120 days before treatment; active GVHD or ongoing immunosuppression after allogeneic transplant; prior HSCT and with active VOD/SOS
- Pregnant or breastfeeding females, or those intending pregnancy.
- History of HIV, HBV, or HCV infections generally excluded, except for controlled or resolved cases as defined.
- Uncontrolled infections requiring antibiotics, antivirals, or antifungals at screening through treatment start.
- Significant medical history or complications within six months prior to enrollment, including advanced congestive heart failure (NYHA Class III or higher), recent unstable angina or myocardial infarction, autoimmune diseases requiring systemic immunosuppressive therapy, active or uncontrolled ocular diseases, Grade 3 or 4 peripheral neuropathy, or other poorly controlled conditions as judged by the investigator (e.g., uncontrolled hypertension, diabetes, or arrhythmias).
- Use of other investigational drugs within 14 days or 5 half-lives before treatment.
- Steroid use over 10 mg/day prednisone equivalent within 14 days prior, except limited corticosteroid use with specific tapering guidelines; topical steroids allowed under conditions for CTCL.
- Major surgery, radiotherapy, chemotherapy, or other anti-cancer treatments within 14 days or 5 half-lives before treatment.
- Prior mogamulizumab use within six months before treatment; associated rash must be ruled out if >6 months.
- Known history of Grade ≥ 3 hypersensitivity to mogamulizumab.
- Failure to recover from prior non-hematologic toxicities to Grade 0 or 1 (except alopecia and mild neuropathy).
- Prolonged QT/QTc interval (e.g., QTcF >480 ms).
- Active second primary malignancies except specified non-exclusionary cases.
- CNS involvement.
- Any condition that may impair compliance or study completion as judged by the Investigator.
- Known hypersensitivity to any excipients in the drug formulation.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Part One (Dose Escalation)
In Part 1, safety and tolerability of KK2223 in relapsed/refractory PTCL or CTCL patients will be assessed using a BOIN dose-escalation design. |
Intravenous infusion |
|
Eksperimentell: Part Two (Backfill)
Part 2 will collect additional data, with dose levels and cohort size based on Part 1 results, administering doses approved for tolerability. Backfill cohorts at cleared doses may open, prioritizing Part 1 enrollment. |
Intravenous infusion |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tidsramme: Through study completion, an average of 1.5 years
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 (all 72 potentially treated subjects) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tidsramme: Through study completion, an average of 1.5 years
|
Vital signs (mmHg in Systolic/Diastolic blood pressure) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tidsramme: Through study completion, an average of 1.5 years
|
Pulse rate (beats/min) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tidsramme: Through study completion, an average of 1.5 years
|
Respiratory Rate (breath/min) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tidsramme: Through study completion, an average of 1.5 years
|
Temperature (°Celcius) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tidsramme: Through study completion, an average of 1.5 years
|
ECG parameters (PR interval, QRS interval, QT interval, QTc interval) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Tidsramme: Through study completion, an average of 1.5 years
|
Number of participants with dose-limiting toxicities (DLTs) in Part 1 only (at most 27 participants) and assess maximum tolerated dose (MTD) |
Through study completion, an average of 1.5 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Mean Blood Drug Concentration
Tidsramme: Through study completion, an average of 1.5 years
|
The mean drug concentration in the blood |
Through study completion, an average of 1.5 years
|
|
To evaluate the immunogenicity of KK2223.
Tidsramme: Through study completion, an average of 1.5 years
|
Incidence of Anti drug antibodies (ADA) in blood |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Tidsramme: Through study completion, an average of 1.5 years
|
% in Overall Response Rate (ORR) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Tidsramme: Through study completion, an average of 1.5 years
|
% in Compartment Response (if applicable) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Tidsramme: Through study completion, an average of 1.5 years
|
Time unit (week/month) in Duration of Response (DOR) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Tidsramme: Through study completion, an average of 1.5 years
|
Time unit (week/month) in Time To Next Treatment (TTNT) will be evaluated |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Tidsramme: Through study completion, an average of 1.5 years
|
Time unit (week/month) in Time To Response (TTR) |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Maximum Blood Concentration (Cmax)
Tidsramme: Through study completion, an average of 1.5 years
|
The maximum drug concentration |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Area Under the Concentration-time Curve (AUC)
Tidsramme: Through study completion, an average of 1.5 years
|
A measure of the overall drug exposure over time |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)
Tidsramme: Through study completion, an average of 1.5 years
|
The time taken to reach the maximum drug concentration |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Terminal Half-Life (Thalf)
Tidsramme: Through study completion, an average of 1.5 years
|
The time required for the drug concentration to decrease by 50% |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Clearance (CL)
Tidsramme: Through study completion, an average of 1.5 years
|
Rate of drug elimination from the body |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Volume of Distribution at Steady State (Vss)
Tidsramme: Through study completion, an average of 1.5 years
|
Theoretical volume of distribution at steady state and reflects the extent of drug istribution into tissues |
Through study completion, an average of 1.5 years
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2223-001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
The datasets generated and/or analyzed during the study sponsored by Kyowa Kirin will be available in the Vivli repository, https://vivli.org/ourmember/kyowa-kirin/ as long as conditions of data disclosure specified in the policy section of the Vivli website are satisfied.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .